The tetanus antibody levels in the people living with HIV in a Turkish HIV care centre


Creative Commons License

Nazlı A., Kenanoglu B., Işıkgöz Taşbakan M., Pullukçu H., Zeytinoğlu A., Gökengin D.

31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 9 - 12 Temmuz 2021, ss.5

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Sayfa Sayıları: ss.5
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

03325 The tetanus antibody levels in the people living with HIV in a Turkish HIV care centre 10. Immunology & Vaccinology A. Nazli 1, B. Kenanoglu 2, M. Isikgoz Tasbakan 2, H. Pullukcu 2, A. Zeytinoglu 3, D. Gokengin 3 1Dokuz Eylul University Medical Faculty Infectious Diseases and Clinical Microbiology Department - Izmir (Turkey), 2Ege University Medical Faculty Infectious Diseases and Clinical Microbiology Department - Izmir (Turkey), 3Ege University Medical Faculty Medical Microbiology Department - Izmir (Turkey) Background Even in the golden age highly active antiretroviral therapy, the people living with HIV have risk of complications from vaccine-preventable diseases. In Turkey, adults were routinely vaccinated during pregnancy or military service and recommended a rappel dose after 10 years. There is a lack of routine vaccination program for the people living with HIV. We aimed to investigate the levels of tetanus antibody levels and the factors related in the people living with HIV who attended our centre. Methods We included the people living with HIV who attended Ege University Medical Faculty Infectious Disease HIV care outpatient clinic who accepted the informed consent to give blood sample. We used Enzyme-Linked Immuno Sorbent Assay kit to test tetanus antitoxin IgG levels. We recorded age, sex, the vaccination history, CD4 T cell count during vaccination, the time of HIV diagnosis retrospectively. Results We included 146 people living with HIV in our study. The 86, 3% was male sex. The mean age was 39.5 years (±11.20). The mean CD4 T cell count was 485 ±279.18 (1- 1331) / mm3. One hundred and fourteen (78.1%) participants had the protective antibody level. The rappel dose recommendations according to antibody level were immediate rappel dose to 32 (21.9%), in five years to 37(25.3%), in ten years to 69 (47.3%) and after ten years to eight (5.5%) participants. In the multi variate analysis, the related factors for protective antibody level were CD4 T cell count >218/ mm3 during vaccination (p= 0,043, OR: 4.28; 95 % CI(1,05-17,44) and age ≥ 43 years (p= 0,0001, OR:30,6 (6,51-144,2). One hundred seven (73.2 %) participants had vaccination history. The duration of vaccination and the antibody levels were uncorrelated. Conclusions The protective antibody levels for tetanus vaccine were low independent of the vaccination time in the people living with HIV. In every five years, testing of tetanus antibody level or rappel dose can protect them for the future infections.